Literature DB >> 19305697

Income-based drug coverage in British Columbia: the impact on access to medicines.

Patricia A Caetano1, Colette B Raymond, Steve Morgan, Lixiang Yan.   

Abstract

BACKGROUND AND OBJECTIVES: In May 2003, the government of British Columbia adopted income-based pharmacare, replacing an age-based program. Stated policy goals included the maintenance or enhancement of access to necessary medicines. This study examines the policy impact on access to two widely used drugs for chronic risk factors (antihypertensives and statins).
METHODS: Data on incident antihypertensive and statin prescriptions between 1997 and 2004 were extracted from PharmaNet. Incident antihypertensive users were those who filled a first prescription after residing in the province for at least two years prior to the initial prescription date. The number of patients who ceased to fill a contiguous series of prescriptions (within 120 days of one another) was used as a measure of apparent discontinuation or interruption of therapy. We used time series analysis to test for changes in incident use and discontinuation.
RESULTS: Between 1997 and 2004, 530,167 BC residents initiated therapy with an antihypertensive, and 264,904 BC residents initiated therapy with a statin. The 2003 policy change had no statistically significant impact on incident use of antihypertensives or statins, when stratified by age or income. Similarly, the 2003 policy did not change the rate of apparent discontinuations of therapy across age and income groups. However, a co-payment introduced in 2002 did increase end-of-year seasonality in apparent discontinuations in seniors--a finding that deserves further research. DISCUSSION: The 2003 transition to income-based pharmacare in British Columbia did not result in significant changes in access to, or continuation of, prescriptions to treat two leading chronic risk factors.

Entities:  

Year:  2006        PMID: 19305697      PMCID: PMC2585444     

Source DB:  PubMed          Journal:  Healthc Policy        ISSN: 1715-6572


  13 in total

Review 1.  The impact of pharmacotherapy policy: a case study.

Authors:  R Tamblyn
Journal:  Can J Clin Pharmacol       Date:  2001

2.  Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update.

Authors:  Jacques Genest; Jiri Frohlich; George Fodor; Ruth McPherson
Journal:  CMAJ       Date:  2003-10-28       Impact factor: 8.262

3.  Income-based drug coverage in British Columbia: the impact on private and public expenditures.

Authors:  Steve Morgan; Lixiang Yan
Journal:  Healthc Policy       Date:  2006-11

4.  Income-Based Drug Coverage in British Columbia: Lessons for BC and the Rest of Canada.

Authors:  Steve Morgan; Robert G Evans; Gillian E Hanley; Patricia A Caetano; Charlyn Black
Journal:  Healthc Policy       Date:  2006-11

5.  Persistence with hypertension treatment among community-dwelling BC seniors.

Authors:  Steven G Morgan; Lixiang Yan
Journal:  Can J Clin Pharmacol       Date:  2004-12-13

6.  Adverse events associated with prescription drug cost-sharing among poor and elderly persons.

Authors:  R Tamblyn; R Laprise; J A Hanley; M Abrahamowicz; S Scott; N Mayo; J Hurley; R Grad; E Latimer; R Perreault; P McLeod; A Huang; P Larochelle; L Mallet
Journal:  JAMA       Date:  2001 Jan 24-31       Impact factor: 56.272

7.  Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization.

Authors:  Sebastian Schneeweiss; Stephen B Soumerai; Robert J Glynn; Malcolm Maclure; Colin Dormuth; Alexander M Walker
Journal:  CMAJ       Date:  2002-03-19       Impact factor: 8.262

8.  Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors.

Authors:  Sebastian Schneeweiss; Alexander M Walker; Robert J Glynn; Malcolm Maclure; Colin Dormuth; Stephen B Soumerai
Journal:  N Engl J Med       Date:  2002-03-14       Impact factor: 91.245

9.  Adherence with statin therapy in elderly patients with and without acute coronary syndromes.

Authors:  Cynthia A Jackevicius; Muhammad Mamdani; Jack V Tu
Journal:  JAMA       Date:  2002 Jul 24-31       Impact factor: 56.272

10.  Income-based drug coverage in british columbia: towards an understanding of the policy.

Authors:  Steve Morgan; Megan Coombes
Journal:  Healthc Policy       Date:  2006-11
View more
  6 in total

1.  Income-based drug coverage in British Columbia: the impact on private and public expenditures.

Authors:  Steve Morgan; Lixiang Yan
Journal:  Healthc Policy       Date:  2006-11

2.  Income-based drug coverage in British Columbia: the impact on the distribution of financial burden.

Authors:  Gillian E Hanley; Steve Morgan; Lixiang Yan
Journal:  Healthc Policy       Date:  2006-11

3.  Income-Based Drug Coverage in British Columbia: Lessons for BC and the Rest of Canada.

Authors:  Steve Morgan; Robert G Evans; Gillian E Hanley; Patricia A Caetano; Charlyn Black
Journal:  Healthc Policy       Date:  2006-11

4.  British Columbia's PharmaCare Program: fair or foul?

Authors:  Brian Hutchison
Journal:  Healthc Policy       Date:  2006-11

5.  Income-based drug coverage in british columbia: towards an understanding of the policy.

Authors:  Steve Morgan; Megan Coombes
Journal:  Healthc Policy       Date:  2006-11

6.  Can income-based co-payment rates improve disparity? The case of the choice between brand-name and generic drugs.

Authors:  Yuki Ito; Konan Hara; Byung-Kwang Yoo; Jun Tomio; Yasuki Kobayashi
Journal:  BMC Health Serv Res       Date:  2019-11-01       Impact factor: 2.908

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.